At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 134 enrolled
Drug / intervention
sitagliptin phosphate +3 moredrug
Likely dose
sitagliptin phosphate 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
MK0431 (Sitagliptin) Phase III Clinical Study -Pioglitazone add-on Study for Patients With Type 2 Diabetes Mellitus
In Brief
A Phase 3 clinical trial evaluating sitagliptin phosphate, Comparator: sitagliptin phosphate (MK0431), and 2 other interventions for Type 2 Diabetes Mellitus. Completed, enrolled 134 participants.
Detailed Summary
The clinical study determines the safety and efficacy of MK0431 in patients with type 2 diabetes mellitus who have inadequate glycemic control on pioglitazone as monotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2006
First PostedSep 2006
Primary CompletionFeb 2008
TodayJul 2026
First PostedSep 6, 2006
Enrollment StartAug 21, 2006
Primary CompletionFeb 5, 2008
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 19.8 years ago
Interventions
sitagliptin phosphatedrug
Sitagliptin (MK0431) 50 or 100 mg once daily for 52 weeks
Comparator: sitagliptin phosphate (MK0431)drug
Sitagliptin (MK0431) 50 or 100 mg once daily for 40 weeks
Comparator: pioglitazonedrug
pioglitazone once daily for 52 weeks
Comparator: placebo (unspecified)drug
Placebo once daily for 12 weeks